On July 1, 2026, the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge Program — a temporary demonstration giving eligible Medicare beneficiaries access to certain weight-loss medications for a flat $50 monthly copay.
It is, on its face, a meaningful expansion of access to drugs that have changed the standard of care for obesity and related conditions. It is also more complicated, more limited, and more temporary than most of the early news coverage suggested. For plan sponsors, TPAs, and the retirees and members they serve, understanding the actual mechanics of this program, and its pitfalls, matters.
